Expand All
    • Clavulox LC is an antibiotic intramammary product for the treatment of clinical mastitis in lactating dairy cows.
    • Clavulox LC has a short 48 hour (4 milking) milk withholding period. This means milk from mastitis affected cows is returned to the vat sooner after treatment, and less milk is discarded due to withholding requirements.
    • It also has a short 7-day meat withholding period, giving producers greater flexibility.
    • Clavulox LC is trusted worldwide due to its broad spectrum efficacy against bacteria commonly isolated in the bovine udder, making it a reliable first line treatment choice.
  • Clavulox LC is specially formulated for the treatment of mastitis in lactating cows. It has a broad spectrum of bactericidal activity against the bacteria commonly isolated from the bovine udder. Clavulox LC is not indicated for cases involvingPseudomonasspp.

    Clavulox LC is active against a wide range of clinically important bacteria, including the following organisms, which are commonly associated with bovine mastitis:

    • Staphylococci (including β-lactamase producing strains).
    • Streptococci (includingS. agalactiae, S. dysgalactiaeandS. uberis).
    • Actinomyces (Corynebacteria) (includingA. pyogenes)
    • Escherichia coli(including β-lactamase producing strains).

    In addition, it is active in vitro against many less common udder pathogens including:Bacillus cereus,Bacteroides(including β-lactamase producing strains),Campylobacterspp., Klebsiellae and Pasteurellae.

    Clavulox LC has been shown to be an effective routine treatment for mastitis in lactating cows. Cases responding successfully to treatment include infections with the following major pathogens:

    • Staphylococci (including β-lactamase producing strains).
    • Streptococci (includingS. agalactiae, S. dysgalactiaeandS. uberis).
    • Escherichia coli(including β-lactamase producing strains).
  • Clavulox LC contains a well trusted antibiotic combination, specifically formulated for the treatment of mastitis in lactating cows. It contains amoxicillin and clavulanic acid in a sterile suspension, presented in an easy to use syringe, specifically designed for intramammary infusion.

    Resistance to many antibiotics is caused by β-lactamase enzymes produced by bacteria. These enzymes destroy the antibiotic before it can act on the bacteria. The clavulanate in Clavulox LC counteracts this defence mechanism by inactivating the β-lactamases, thus rendering the bacteria sensitive to amoxycillin’s rapid bactericidal effect at concentrations readily attainable in the udder.

  • Clavulox LC is a sterile suspension suitable for intramammary infusion. It is presented in disposable syringes, each containing 200 mg amoxycillin as amoxycillin trihydrate and 50 mg clavulanic acid as potassium clavulanate in a quick release base.

    There are 24 syringes per box.

  • Dose: A course of 3 syringes per infected quarter. One syringe to be infused every 12 hours.

    Administration: After milking, clean and disinfect the teat with an approved teat disinfectant, insert the nozzle into the teat canal and apply gentle and continuous pressure on the plunger until all the suspension is expressed. Wear sanitised rubber gloves when applying. Dip all teats after infusing with an approved teat disinfectant.
    The treated quarter(s) should be milked out at the next normal milking, and milk withheld from the general collection.

    • Storage:
      Store below 25°C (Air Conditioning)
    • Schedule:
    • Withholding period: MEAT: DO NOT USE less than 7 days before slaughter for human consumption. MILK: Milk taken from cows within 48 hours (4 milkings) following last treatment MUST NOT BE USED for human consumption, supplied for processing or fed to calves which will be slaughtered for human consumption within 7 days
    • TRADE ADVICE: EXPORT SLAUGHTER INTERVAL (ESI): This product does not have an ESI established. For advice on the ESI, contact the manufacturer on 1800 884 813 before using this product.
A Better Way To Buy